ETFS S&P Biotech ETF (CURE:AU) Annual Income Statement ()
CURE:AU Quarterly Financials ()
Frequently Asked Questions About ETFS S&P Biotech ETF (CURE:AU) Stock
ETFS S&P Biotech ETF's (CURE:AU) last reported annual revenue was N/A.
ETFS S&P Biotech ETF's (CURE:AU) annual revenue growth rate based on the revenue reported in the past 5 years is : N/A
ETFS S&P Biotech ETF's(CURE:AU) is not profitable as of its last reported annual financials.
The net profit margin for ETFS S&P Biotech ETF's(CURE:AU) from its laster reported year is N/A
The return on equity (ROE) for ETFS S&P Biotech ETF's(CURE:AU) from its last reported annual financials is : N/A
The return on assets (ROA) for ETFS S&P Biotech ETF's(CURE:AU) from its last reported annual financials is : N/A
The return on invested capital (ROIC) for ETFS S&P Biotech ETF's(CURE:AU) from its last reported annual financials is : N/A
The Debt to Equity ratio for ETFS S&P Biotech ETF's(CURE:AU) from its last reported annual financials is : N/A
The dividend yield for ETFS S&P Biotech ETF's(CURE:AU) from its laster reported year is 0.00%
ETFS S&P Biotech ETF's(CURE:AU) has negative cash flow as of its last reported annual financials.
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
There is nothing we particularly like
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for CURE:AU !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
Stocktwits
